Authorization

Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Companya??) (TSXV:ATE,
OTCQB:ATBPF), a leader in developing safer therapeutics for pain and
inflammation, is pleased to announce that its Phase 2B dose-ranging,
efficacy study for ATB-346 has formally commenced. Enrollment is open,
clinical sites have been activated and patients will now begin screening.


The study is designed to validate the efficacy of ATB-346 in reducing
osteoarthritis ("OAa??) pain and establish the dose for Phase 3
development. The study will involve a total of 360 patients with OA of
the knee, who will be randomized to placebo or one of three doses of
ATB-346 administered once daily: 150 mg, 200 mg or 250 mg.


"We are excited to officially commence the final Phase 2 study for
ATB-346,a?? commented Dan Legault, Antibea??s CEO. "A successful outcome in
this large clinical trial will further validate the best-in-class
potential of ATB-346, and will represent a major inflection point as we
position ourselves for Phase 3 development and global partnering
discussions.a??


The study is being conducted by Veristat, Inc. ("Veristata??) in
approximately 35 clinical sites across Canada and is expected to have a
top-line data read-out this summer.


About ATB-346


ATB-346 is a hydrogen sulfide-releasing derivative of naproxen.
Nonsteroidal anti-inflammatory drugs ("NSAIDsa??) are the most commonly
used therapy for osteoarthritis, but their use is associated with a high
incidence of gastrointestinal ulceration and bleeding. NSAIDs are also
widely used in conditions such as rheumatoid arthritis, ankylosing
spondylitis, gout, and general pain reduction, with a similarly high
rate of gastrointestinal ulceration and bleeding. It is well-accepted
that patients with these conditions would benefit greatly from an
effective, non-addictive, GI-sparing anti-inflammatory/analgesic agent
such as ATB-346.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2019    »
ПнВтСрЧтПтСбВс
1234567
891011121314
15161718192021
22232425262728
2930